Company intelligence / Profile preview

TECH-ILA

Ownership: Private
Development stage: Other

Overview

ILA is developing a therapeutic for dengue fever. The lead candidate has completed multiple safety studies and is currently undergoing Phase 2a/b trials. Results from these trials are expected soon, with plans to potentially move into Phase 3 as either a preventative or therapeutic agent. The drug could also be eligible for the FDA’s Priority Review Voucher program due to its focus on neglected tropical diseases like dengue. There are ambitions to expand into other infectious disease indications and the biodefense sector.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Potential partnerships anticipated for late-stage clinical development but none named yet

Beyond the preview

Go deeper on TECH-ILA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TECH-ILA.

Explore the full profile